Amanote Research
Register
Sign In
Prm118 - Adjustment for Subsequent Therapies Received: The Impact on Outcomes of an Economic Model of Nivolumab+ipilimumab in First Line Renal Cell Carcinoma
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.2238
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
H Cawston
V Genestier
P Dale
J Doan
B Malcolm
Publisher
Elsevier BV